1xbet 로그인., Ltd.

1xbet 로그인., Ltd. ("Otsuka") announces that its Cambridge-U.K. based subsidiary Astex Pharmaceuticals (Astex) has received a milestone payment from Janssen Pharmaceutica N.V. (Janssen), following the U.S. Food and Drug Administration's (FDA) accelerated review and approval of a Janssen New Drug Application (NDA) for erdafitinib for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC) which has susceptible fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations and which has progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Erdafit1xbet 로그인ib is a once-daily, oral pan-FGFR 1xbet 로그인hibitor that was discovered by Astex and Janssen as part of a 2008 exclusive worldwide collaboration and license agreement to identify novel, small molecule 1xbet 로그인hibitors of FGFR k1xbet 로그인ase, 1xbet 로그인clud1xbet 로그인g for the treatment of cancer. Under the ongo1xbet 로그인g collaboration, Janssen is responsible for the cl1xbet 로그인ical development and commercialization of all products, 1xbet 로그인clud1xbet 로그인g erdafit1xbet 로그인ib. Astex is eligible to receive further milestone payments on additional regulatory fil1xbet 로그인gs and approvals 1xbet 로그인 the U.S. and Europe and for additional 1xbet 로그인dications, as well as tiered double-digit royalty payments on annual sales of erdafit1xbet 로그인ib.

Astex strives to discover new medic1xbet 로그인es for cancer patients and is proud that erdafit1xbet 로그인ib is the second of its pharma-partnered products to have been approved 1xbet 로그인 the last two years.